Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7
VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
VolitionRX Ltd, Medical Equipment, Deal Details 11
Partnerships 11
VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 11
VolitionRx Enters into Distribution Agreement with Active Motif 12
VolitionRx Enters into Co-Development Agreement with University of Oxford 13
VolitionRx Enters Into Distribution Agreement With Active Motif For NuQ Product Line 14
VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers For Cancer 15
Equity Offering 16
VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16
VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17
VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18
VolitionRX Raises USD8.4 Million in Public Offering of Shares 19
VolitionRX Raises USD0.5 Million in Private Placement of Shares upon Exercise of Warrants 20
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 21
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 22
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 23
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 24
VolitionRX Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 25
VolitionRx Raises USD14.1 Million in Public Offering of Shares 27
VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 29
VolitionRx Completes Private Placement Of Shares For US$3 Million 31
VolitionRX Completes Private Placement Of Shares For US$0.6 Million 32
VolitionRX Completes Private Placement Of Shares For US$0.4 Million 33
VolitionRX Completes Private Placement Of Shares For US$0.5 Million 34
VolitionRX Completes Private Placement Of Shares For US$1 Million 35
VolitionRX Completes Private Placement Of Units For US$1.2 Million 36
Acquisition 37
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 37
VolitionRX Ltd – Key Competitors 38
VolitionRX Ltd – Key Employees 39
VolitionRX Ltd – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Strategy And Business Planning 41
Sep 19, 2017: VolitionRx Announces its European Colorectal Cancer Strategy 41
Financial Announcements 42
Aug 13, 2018: VolitionRx announces second quarter 2018 financial results and business update 42
May 10, 2018: VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update 44
Nov 09, 2017: VolitionRx Announces Third Quarter 2017 Financial Results and Business Update 45
Aug 09, 2017: VolitionRx Announces Second Quarter 2017 Financial Results and Business Update 47
May 11, 2017: VolitionRx Announces First Quarter 2017 Financial Results and Business Update 48
Mar 10, 2017: VolitionRx Announces Full Fiscal Year 2016 Financial Results and Business Update 49
Corporate Communications 50
Mar 07, 2018: VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board 50
Apr 11, 2017: VolitionRx Appoints David Vanston as Chief Financial Officer 51
Product News 52
Feb 26, 2018: VolitionRx Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer 52
Feb 05, 2018: VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark 54
Sep 14, 2017: Volition Granted Four Additional Patents 55
Jun 30, 2017: Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress 56
May 18, 2017: A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition’s Nu.Q assays 57
Other Significant Developments 58
May 09, 2018: VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits 58
Mar 01, 2018: VolitionRX Announces Full Fiscal Year 2017 Financial Results and Business Update 59
Sep 22, 2017: VolitionRx Announces the Initial Sale of its New Nu.Q Research Kits 61
Sep 21, 2017: VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding 62
Aug 22, 2017: Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers 63
Mar 28, 2017: Volition America Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65
VolitionRX Ltd, Medical Equipment, Key Facts, 2017 2
VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7
VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Deals By Market, 2012 to YTD 2018 9
VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 11
VolitionRx Enters into Distribution Agreement with Active Motif 12
VolitionRx Enters into Co-Development Agreement with University of Oxford 13
VolitionRx Enters Into Distribution Agreement With Active Motif For NuQ Product Line 14
VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers For Cancer 15
VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16
VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17
VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18
VolitionRX Raises USD8.4 Million in Public Offering of Shares 19
VolitionRX Raises USD0.5 Million in Private Placement of Shares upon Exercise of Warrants 20
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 21
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 22
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 23
VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 24
VolitionRX Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 25
VolitionRx Raises USD14.1 Million in Public Offering of Shares 27
VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 29
VolitionRx Completes Private Placement Of Shares For US$3 Million 31
VolitionRX Completes Private Placement Of Shares For US$0.6 Million 32
VolitionRX Completes Private Placement Of Shares For US$0.4 Million 33
VolitionRX Completes Private Placement Of Shares For US$0.5 Million 34
VolitionRX Completes Private Placement Of Shares For US$1 Million 35
VolitionRX Completes Private Placement Of Units For US$1.2 Million 36
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 37
VolitionRX Ltd, Key Competitors 38
VolitionRX Ltd, Key Employees 39
VolitionRX Ltd, Subsidiaries 40
List of Figures
VolitionRX Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
VolitionRX Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9
